HMBD 802
Alternative Names: HMBD-802Latest Information Update: 20 Mar 2025
At a glance
- Originator Hummingbird Bioscience
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; Ataxia telangiectasia mutated protein inhibitors; DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 03 Mar 2025 Antibody-drug conjugate licensed to Callio Therapeutics
- 28 Oct 2024 Preclinical trials in Cancer in Singapore (unspecified route)
- 23 Oct 2024 Safety and pharmacodynamics data from preclinical trials in Cancer presented at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR Symposium-2024)